Literature DB >> 19184380

Simple and sensitive spectrofluorimetric method for the determination of oseltamivir phosphate in capsules through derivatization with fluorescamine.

Zeynep Aydoğmuş1.   

Abstract

A new, simple and sensitive spectrofluorimetric method has been developed for the determination of oseltamivir phosphate (OSP) in capsules. The method is based on the reaction between oseltamivir and fluorescamine in borate buffer solution of pH 8.50 to give highly fluorescent derivatives that are measured at 483 nm using an excitation wavelength of 381. The different experimental parameters effecting the development and stability of the reaction product were carefully studied and optimized. The fluorescence intensity concentration plot is rectilinear over the range 50-450 ng mL(-1) with a lower detection limit (LOD) of 1.219 ng mL(-1) and limit of quantitation (LOQ) of 4.064 ng mL(-1). Selectivity was validated by subjecting stock solution of OSP to acidic, basic, oxidative, and thermal degradation. No interference was observed from excipients present in formulations. The developed method was successfully applied to determination of the drug in capsules. The mean % recovery (n = 6) was 100.08. The results obtained were in good agreement with those obtained using a reported spectrophotometric method.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19184380     DOI: 10.1007/s10895-009-0461-3

Source DB:  PubMed          Journal:  J Fluoresc        ISSN: 1053-0509            Impact factor:   2.217


  15 in total

Review 1.  Oseltamivir: a review of its use in influenza.

Authors:  K McClellan; C M Perry
Journal:  Drugs       Date:  2001       Impact factor: 9.546

2.  A simple and rapid liquid chromatographic assay for evaluation of potentially counterfeit Tamiflu.

Authors:  N Lindegårdh; T T Hien; J Farrar; P Singhasivanon; N J White; N P J Day
Journal:  J Pharm Biomed Anal       Date:  2006-06-05       Impact factor: 3.935

3.  Development of a high-performance liquid chromatographic-mass spectrometric assay for the specific and sensitive quantification of Ro 64-0802, an anti-influenza drug, and its pro-drug, oseltamivir, in human and animal plasma and urine.

Authors:  H Wiltshire; B Wiltshire; A Citron; T Clarke; C Serpe; D Gray; W Herron
Journal:  J Chromatogr B Biomed Sci Appl       Date:  2000-08-18

4.  Identification of GS 4104 as an orally bioavailable prodrug of the influenza virus neuraminidase inhibitor GS 4071.

Authors:  W Li; P A Escarpe; E J Eisenberg; K C Cundy; C Sweet; K J Jakeman; J Merson; W Lew; M Williams; L Zhang; C U Kim; N Bischofberger; M S Chen; D B Mendel
Journal:  Antimicrob Agents Chemother       Date:  1998-03       Impact factor: 5.191

5.  Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group.

Authors:  K G Nicholson; F Y Aoki; A D Osterhaus; S Trottier; O Carewicz; C H Mercier; A Rode; N Kinnersley; P Ward
Journal:  Lancet       Date:  2000-05-27       Impact factor: 79.321

6.  High-performance liquid chromatographic determination of GS4071, a potent inhibitor of influenza neuraminidase, in plasma by precolumn fluorescence derivatization with naphthalenedialdehyde.

Authors:  E J Eisenberg; K C Cundy
Journal:  J Chromatogr B Biomed Sci Appl       Date:  1998-09-25

7.  Analysis of oseltamivir active metabolite, oseltamivir carboxylate, in biological materials by HPLC-UV in a case of death following ingestion of Tamiflu.

Authors:  Chiaki Fuke; Yoko Ihama; Tetsuji Miyazaki
Journal:  Leg Med (Tokyo)       Date:  2007-08-27       Impact factor: 1.376

8.  Development and validation of a liquid chromatographic-tandem mass spectrometric method for determination of oseltamivir and its metabolite oseltamivir carboxylate in plasma, saliva and urine.

Authors:  N Lindegårdh; W Hanpithakpong; Y Wattanagoon; P Singhasivanon; N J White; N P J Day
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2007-09-19       Impact factor: 3.205

9.  Stability indicating RP-HPLC method development and validation for oseltamivir API.

Authors:  Balasubramanian Narasimhan; Khan Abida; Kona Srinivas
Journal:  Chem Pharm Bull (Tokyo)       Date:  2008-04       Impact factor: 1.645

10.  Determination of oseltamivir carboxylic acid in human serum by solid phase extraction and high performance liquid chromatography with UV detection.

Authors:  Gholamreza Bahrami; Bahareh Mohammadi; Amir Kiani
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2008-02-08       Impact factor: 3.205

View more
  4 in total

1.  Spectrofluorimetric methods for the determination of gemifloxacin in tablets and spiked plasma samples.

Authors:  Serife Evrim Kepekci Tekkeli; Armağan Önal
Journal:  J Fluoresc       Date:  2010-10-28       Impact factor: 2.217

2.  Selectivity Improvement for Spectrofluorimetric Determination of Oseltamivir Phosphate in Human Plasma and in the Presence of Its Degradation Product.

Authors:  Mahmoud A Omar; Sayed M Derayea; Islam M Mostafa
Journal:  J Fluoresc       Date:  2017-03-14       Impact factor: 2.217

3.  Behaviours of antiviral Oseltamivir in different media: DFT and SQMFF calculations.

Authors:  Mohammad Vakili; Elida Romano; Vahidreza Darugar; Silvia Antonia Brandán
Journal:  J Mol Model       Date:  2021-11-23       Impact factor: 1.810

4.  Utility of Experimental Design in Pre-Column Derivatization for the Analysis of Tobramycin by HPLC-Fluorescence Detection: Application to Ophthalmic Solution and Human Plasma.

Authors:  Asmaa A El-Zaher; Marianne A Mahrouse
Journal:  Anal Chem Insights       Date:  2013-04-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.